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1. Introduction
  Primary hepatocellular carcinoma (HCC) is one of the 
most common malignancy in the world, its incidence and 
mortality rank the second of all cancers, which is a serious 
threat to people’s health. The first options of treatment 
for HCC is still surgery, but the surgical resection rate 
is low, and the recurrence rate postoperative is high, 
so the death rate is always high[1,2]. So it is extremely 
important to explore the pathogenesis of HCC and look 
for new drugs. This article detected the silent information 
regulator protein 3 (SIRT3) expression of primary HCC by 
immunohistochemistry and Western-blotting, in order to 
understand the possible role of SIRT3 in the process and 
development of liver cancer.
2. Materials and methods
2.1. Materials
  In this study, all samples were taken from tissues of 
patients who underwent surgical removal from January 2011 
to December 2012, and diagnosed with primary HCC by 
pathological analysis. All patients with HCC did not receive 
preoperative treatment programs such as chemotherapy, 
radiation or radio frequency. Cancer adjacent tissues 
without necrosis (the distance was beyond 2 cm from 
Objective: To observe expression of SIRT3 in normal liver tissue, cirrhotic tissue and 
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expression of SIRT3 is closely related to the biological behavior of primary HCC.
 Bo Zhang et al./Asian Pacific Journal of Tropical Medicine (2013)649-652650
tumor specimen edge) were taken as the paracancer group. 
Specimens of 10 normal liver tissues of patients suffering 
from surgical resection at the same period in our hospital 
were selected as the normal group. Part of them were fixed 
in 10% formalin, dehydrated and embedded in paraffin, 3-4 
毺m sections were prepared for immunohistochemical assay; 
Part of them were collected from the body within half an 
hour after surgical resection, immediately quick-frozen in 




 Mouse anti-human SIRT3 monoclonal antibody was 
purchased from Thermo, fluorescence-labeled goat anti-
mouse secondary antibody were purchased from Genomics 
Company. Immunohistochemistry kit was purchased from 
Sigma, USA. Total protein extraction kits were purchased 
from Invitrogen Corporation.
2.3. Immunohistochemistry method
  Immunohistochemistry was adopted as follows: The antigen 
of all specimens were repaired by high temperature and 
high pressure, and then stained in accordance with the 
instructions. The SIRT3 protein staining was mainly located 
in cytoplasm, which was yellow or brown. SIRT3-positive 
cells cytoplasm showed brown or brown-yellow particles, 
otherwise they were considered to be SIRT3-negative cells. 
Double-blind method was adopted by two experienced 
pathologist, and then the results were determined by semi-
quantitative method. Five randomly visions (400暳) of each 
tissue section were observed, at least 1 000 cells were 
counted, and the percentage of positive cells was calculated. 
Positive degree of tumor cells from 10% to 25% were (+), from 
26% to 50% were (++), more than 51% were (+++); positive cells 
rate of section 曒10% were regarded as positive, <10% as 
negative (-).
2.4. Western-blotting
  Liver tissue was removed from the liquid nitrogen, and 
cut approximately to 50 mg. It was added to homogenate 
protein by the ratio of 1:9, the total protein was extracted 
for protein quantification. It was denatured at 95-100 曟  for 
5 min, 30 毺g total protein were taken from each group for 
electrophoretic, transfer and BSA blocking. Mouse anti-
human SIRT3 monoclonal antibody was added, and diluted 
at 1:1 000. It was gently shaked at 4 曟, incubated overnight, 
and added with second antibody after washing. They were 
diluted at 1:5 000. Avoid light, it was incubated for 1 h at 
room temperature, and then was washed. With 毬-actin as 
an internal control, the gray integral value of each stripe 
were automatically read and recorded by the computer, 
statistical analysis was conducted based on sample integral 
value/internal reference ratio.
2.5. Statistical analysis
  All of the data were analyzed by SPSS 11.5 statistics 
software. t-test, 氈
2 examination, exact probabilities and the 
Spearman rank correlation analysis were applied. P<0.05 
was considered as statistical significance.
3. Results
3.1. SIRT3 protein expression 
  Immunohistochemical results showed that SIRT3 
expressions were all positive in normal group, the positive 
expression rate was 100.0%. A total of 29 cases were positive 
in paracancer group (96.7%), and 18 cases were positive in 
HCC group (60.0%). SIRT3 positive rate and the mean score 
of tissues in HCC group was significant higher than those of 
other two groups (P<0.05) (Table 1).
  Western-blotting experimental results showed that SIRT3 
protein relative expression in HCC group (SIRT3/毬-actin) 
was 0.29暲0.07, which was significantly lower than in 





- + ++ +++
HCC group 12 15   3   0
Paracancer group   1   2 11 16
Normal group   0   1   1   8
3.2. Relationship between SIRT3 protein expression and 
clinical pathological features of primary HCC
  Immunohistochemistry and Westem-boltting showed 
that SIRT3 protein relative expression gradually decreased 
with the degree of the differentiation of hepatoma cell. In 
hepatoma cells with various differentiation degree, the 
differences of the SIRT3 protein relative expressions had 
statistically significant (P<0 05). The statistical analysis 
showed patients with portal vein tumor thrombus had 
significantly lower positive expression rate and relative 
expression (P<0.05). There was no significant difference 
between SIRT3 protein expression and age, sex, liver size 
and AFP values (P>0.05) (Table 2).
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4. Discussion
  Silent information regulator factor family (Sirtuins) is a 
highly conserved protein family, which contain a conserved 
catalytic core domain, and according to its subcellular 
localization, it is divided into seven subtypes[3]. The studies 
suggest that Sirtuins (SirT) involved in the regulation of 
life, SIRT3 as a potential tumor inhibitors attracting more 
and more attention in recent years. SIRT3 is the main 
histone deactylase of the mammalian mitochondrial, it 
can participate in amino acid metabolism by adjusting 
the enzyme activity, and also participate in the protein 
metabolism adjust of entire body by the regulation of 
cell autophagy. The substrates mainly include glutamate 
dehydrogenase and succinate deoxy enzymes. They can 
activate the transferase activity of the deacetylation enzymes 
and ribosomes to achieve post-translational regulation of 
the target protein[4-6].
  Mice with the SIRT3 knockouted was more susceptible 
to cancer if they received many stress.SIRT3 in tumor 
cells decreased significantly compared with in the normal 
tissue cells, which showed that the SIRT3 may have tumor 
suppressor function in the body. Once the body lose the 
SIRT3-mediated regulation of mitochondrial protein, it may 
lead to oncogene infection, and that lead to immortalization 
and transformation. Therefore members of histone deactylase 
family plays an important role in development of tumor[7-10].
  Immunohistochemical results showed that SIRT3 SIRT3 
positive rate and the mean score of tissues in HCC group was 
significant higher than those of other two groups (P<0.05). 
Western-blotting experimental results showed that SIRT3 
protein relative expression of 30 cases in the hcc group 
(SIRT3/毬-actin) was also significant higher than those of 
other two groups (P<0.05). The SIRT3 protein expression of 
the cirrhotic tissue was slightly lower than the normal group, 
but the difference had no statistically significant (P>0.05).
  The immunohistochemistry and Westem-bloting results 
showed there was no significantly different of SIRT3 
expression between the normal liver tissues and the cirrhotic 
tissue, and there was significantly low expression in HCC 
tissues. Immunohistochemical assay showed the positive 
expressions were mainly weakly positive, and there was 
no significant expression, which is consistent with other 
studies. There was no significant change of the SIRT3 protein 
expression levels during the development process from 
normal liver tissue to liver cirrhosis, but the expression in 
HCC tissues was decreased or lost, which showed the SIRT3 
protein did not play a biological role in this process from 
the normal liver tissue to cirrhosis. Once the expression was 
decreased or lost, the nature of the cirrhotic liver tissues 
may become carcinogenesis[11].
  In this study, we analyzed the effect of SIRT3 protein 
expression levels on the clinical and pathological features 
of the primary hepatocellular carcinoma. We presume that 
the SIRT3 protein expression in HCC is related with the 
pathological features of liver cancer cell, the differentiation 
degree and complication with portal vein tumor thrombus. 
SIRT3 protein relative expression gradually decreased 
Table 2 
Relationship between SIRT3 protein expression and clinical pathological features of primary HCC.




曒60 12   5 0.28暲0.08 0.18 2.80
<60 18 13 0.29暲0.07
Gender
Male 21 14 0.27暲0.07 1.49 1.30
Female   9   4 0.31暲0.12
Tumor diameter
曒5 cm 13   7 0.28暲0.06 1.45 0.36
<5 cm 17 11 0.30暲0.09
Differentiation degree 
Well-differentiated   8   7 0.35暲0.09 2.24 3.86
moderately differentiated 15   7 0.24暲0.08
Poorly differentiated   7   4 0.17暲0.09
AFP value
曒20 ng / L 20 14 0.27暲0.08 1.36 2.50
<20 ng / L 10   4 0.30暲0.08
Portal vein thrombosis
with   9   2 0.16暲0.09 2.43 7.65
without 21 16 0.34暲0.12
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with the degree of the differentiation of hepatoma cell. 
SIRT3 protein expression level showed the downtrend in 
the deterioration and progression of HCC cells. Therefore, 
we believe that SIRT3 protein also plays a role in the 
progression of liver cancer. Its mechanism may be related 
to reactive oxygen species (ROS) in mitochondrial. The 
occurrence and development of liver cancer are the same 
as other tumors, which is a complex process involved in 
polygenic and multifactorial. But liver cancer still has its 
own characteristics, we summarizes the carcinogenesis of 
various animal models and found that ROS increased almost 
in all of the animal models. Thus we can infer ROS played 
a very important role in the occurrence and development of 
liver cancer[12-14].
  Mitochondria are the main source of ROS in the body. 
Studies have shown that SIRT3 can reduce the level of ROS. 
It is easy to cause mitochondrial metabolic abnormalities 
when cells lack of SIRT3. Cells suffered ROS damage. With 
the increase of ROS, cell damage becomes more severe, and 
there will be mutations of the gene stability in particular 
intracellular environment, and ultimately there will be de-
differentiation and carcinogenesis. This conjecture has been 
confirmed in SIRT3-deficient rats[15-18].
  Therefore, the lack of SIRT3 expression can easily cause 
the occurrence and development of HCC. By revealing 
SIRT3’s anti-tumor mechanism, we try to provide an 
effective method for early diagnosis and treatment of tumor 
in clinic.
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